时空网络动力学揭示了阿尔茨海默病的进展
Theodore J LaGrow1,2, Vaibhavi Itkyal3,4, Harrison Watters4
1School of Electrical and Computer Engineering, Georgia Institute of Technology, 777 Atlantic Dr NW, Atlanta, GA 30332.
bioRxiv : the preprint server for biology
|December 22, 2025
概括
新方法揭示了早期阿尔茨海默氏症 (AD) 网络变化在认知能力下降之前. 准周期性模式 (QPPs) 和复杂主要成分分析 (cPCA) 检测到微妙的脑部变化,以潜在的早期AD检测.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 涉及到前面的认知衰退的渐进性脑网络干扰.
- 传统的功能连接分析往往错过了关键的早期网络协调变化.
- 确定临床前AD生物标志物对于及时干预和治疗至关重要.
研究的目的:
- 在阿尔茨海默病 (AD) 中使用新的分析技术来表征时空网络变化.
- 为了识别早期的网络变化,表明临床前AD进展.
- 为AD建立一个动态的,网络级生物标志物框架.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 队列的静止状态fMRI数据.
- 应用准周期性模式 (QPPs) 来推导时空模板和网络完整性.
- 采用复杂主要成分分析 (cPCA) 来分析大脑活动中的幅度和阶段关系.
主要成果:
- 确定了网络退化的结构性轨迹,对边缘,皮质下和高级认知网络产生早期影响.
- 在正式诊断转换之前,观察到过渡群体的显著变化,表明临床前信息.
- QPP指标突出显示了边缘/下皮层退化,而cPCA显示了高阶,视觉和小脑网络的变化.
结论:
- 结合QPP和cPCA提供了对AD相关网络病理学的补充见解.
- 这些方法检测到的时空特征为早期AD检测提供了潜力.
- 开发的框架可以帮助描述疾病轨迹和监测治疗疗效.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744


